Mutant-prevention concentrations of enrofloxacin for Escherichia coli isolates from chickens

American Journal of Veterinary Research

Volumn 68, Issue 8, 2007, Pages 812-815

  Li, Qianxue ^a,b   Bi, Xingming ^a   Diao, Youjiang ^a   Deng, Xuming ^a  

^a JILIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; ENROFLOXACIN; PROTEIN PARC;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHICKEN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TREATMENT FAILURE; ESCHERICHIA COLI; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE LOCUS; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; WILD TYPE;

ANIMALS; ANTI-BACTERIAL AGENTS; CHICKENS; DNA GYRASE; DNA TOPOISOMERASE IV; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION;

ESCHERICHIA COLI; GALLUS GALLUS;

EID: 34548285029     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.8.812     Document Type: Article

References (24)

1. Gross WB. Colibacillosis. In: Calnek BW ed. Diseases of poultry. 9th ed. Ames, Iowa: Iowa State University Press, 1991;138-144
2. Wolfson J, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989;2:378-424.
3. Cui HB, Zhu H. Fluoroquinolone susceptibility test in Escherichia coli from chickens. Chin J Vet Sci 2002;38:44-45.
4. Fang B, Zeng Z, Feng Q, et al. Efficacy of enrofloxacin against experimentally induced colibacillosis and staphylococcosis in chickens. Chin J Vet Sci 1997;17:157-160.
5. Solomon DH, Van Houten L, Glynn RJ, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med 2001;161:1897-902.
6. Norbert L, Jutta SH, Theresia K, et al. Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance. J Clin Microbiol 1996;34:597-602.
7. Everett MJ, Jin YF, Ricci V, et al. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother 1996;40:2380-2386.
8. Wang H, Joann LD, Chen M, et al. Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of AcrR mutations. Antimicrob Agents Chemother 2001;45:1515-1521.
9. Piddock LJV. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 1999;58:11-18.
10. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996;40:879-885.
11. Oram M, Fisher LM. 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother 1991;35:387-389.
12. Zhao X, Xu C, Domagala J, et al. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A 1997;94:13991-13996.
13. Zhao X, Drlica K. Restricting the selection of antibiotic resistant mutants: a general strategy derived from fluoroquinolone studies. Clinic Infect Dis 2001;33(suppl 3):S147-S156.
14. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003;52:11-17.
15. Drlica K. A strategy for fighting antibiotic resistance. ASM News 2001;67:27-33.
16. Dong Y, Zhao X, Kreisworth BN, et al. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000;44:2581-2584.
17. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard. NCCLS M31-A2. 2nd ed. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2003.
18. Anadon A, Martinez-Larranaga MR, Diaz MJ, et al. Pharmacokinetics and residues of enrofloxacin in chickens. Am J Vet Res 1995; 56:501-506.
19. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-1073.
20. Witte W. Medical consequences of antibiotic use in agriculture. Science 1998;279:996-997.
21. Epstein BJ, Gums JG, Drlica K. The changing face of antibiotic prescribing: the mutant selection window. Ann Pharmacother 2004;38:1675-1682.
22. Drlica K, Zhao X, Blondeau JM, et al. Low correlation between MIC and mutant prevention concentration. Antimicrob Agents Chemother 2006;50:403-404.
23. Bagel S, Hullen V, Wiedemann B, et al. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob Agents Chemother 1999;43:868-875.
24. Hawkey PM. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother 2003;51(suppl 1):29-35.